Table 3.
Comparison of select historical factors for Lynch Syndrome among endometrial cancers by type of immunohistochemical protein loss.
| MLH1/PMS2 No MLH1 methylation N = 15 |
MSH2/MSH6 N = 12 |
MSH6 N = 9 |
PMS2 N = 7 |
p-value | |
|---|---|---|---|---|---|
|
Median age at diagnosis (yrs) (Range) |
62 (43–79) |
56 (42–71) |
62 (50–76) |
56 (45–87) |
0.50 --- |
| BMI < 30 kg/m2 | 4 (26.7%) | 5 (41.6%) | 6 (66.6%) | 2 (28.6%) | 0.29 |
| Family History EC1 | 3 (21.4%) | 0 | 1 (12.5%) | 0 | 0.31 |
| Family History CRC2 | 3 (20%) | 3 (25%) | 1 (12.5%) | 1 (14.3%) | 0.95 |
| LUS3 Tumor | 1 (6.7%) | 1 (8.3%) | 0 | 3 (42.9%) | 0.05 |
| Endometrioid Histology | 13 (86.7%) | 9 (75%) | 8 (88.9%) | 7 (100%) | 0.62 |
| Stage I or II | 13 (86.7%) | 8 (66.7%) | 9 (100%) | 7 (100%) | 0.14 |
| Meets SGO4 5–10% Criteria | 6 (40.0%) | 5 (41.7%) | 2 (22.2%) | 1 (14.3%) | 0.62 |
1
EC; patient has a first- or second-degree relative with a diagnosis of endometrial cancer
2
CRC; patient has a first- or second-degree relative with a diagnosis of colorectal cancer
3
LUS; Tumor arising from lower uterine segment
4
SGO; Society of Gynecologic Oncology